MAIA Biotechnology (NYSEAMERICAN:MAIA) Announces Quarterly Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) issued its quarterly earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01, FiscalAI reports.

MAIA Biotechnology Stock Performance

Shares of MAIA traded up $0.03 during midday trading on Monday, hitting $1.09. The company had a trading volume of 226,201 shares, compared to its average volume of 722,915. The company’s 50-day simple moving average is $1.21 and its 200-day simple moving average is $1.45. The firm has a market capitalization of $67.30 million, a P/E ratio of -1.76 and a beta of 0.28. MAIA Biotechnology has a 1 year low of $0.87 and a 1 year high of $3.19.

Insider Buying and Selling

In other news, CEO Vlad Vitoc purchased 73,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was bought at an average price of $1.37 per share, for a total transaction of $100,010.00. Following the completion of the purchase, the chief executive officer directly owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. The trade was a 7.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ramiro Guerrero purchased 37,595 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The stock was purchased at an average price of $1.32 per share, with a total value of $49,625.40. Following the purchase, the director directly owned 773,296 shares of the company’s stock, valued at $1,020,750.72. The trade was a 5.11% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 258,078 shares of company stock worth $352,426 over the last 90 days. Insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.